Hazelden Betty Ford & Mayo Clinic Set Out To Find Biological Markers For Treatment Of Alcoholism

The Hazelden Betty Ford Foundation has signed an agreement with Mayo Clinic to collaborate on a federally funded research project that could help usher in a new era of addiction medicine. The two national health care leaders will search for genetic markers that predict response to the drug, Acamprosate, which has been shown to help people with alcohol use disorder stay sober. 

The five-year study, coordinated with and funded by grants from the National Institute on Alcohol Abuse and Alcoholism, aims to help addiction care provider organizations understand who, based on a blood test, should receive the medicine and . . .